The FDA on June 15, 2023, granted accelerated approval to COLUMVI® for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, not otherwise specified (DLBCL, NOS) or Large B-Cell Lymphoma (LBCL) arising from Follicular Lymphoma, after two or more lines of systemic therapy. COLUMVI® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
